| __timestamp | Ascendis Pharma A/S | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 10811000 |
| Thursday, January 1, 2015 | 9415000 | 33001000 |
| Friday, January 1, 2016 | 11504000 | 64936000 |
| Sunday, January 1, 2017 | 13482000 | 99909000 |
| Monday, January 1, 2018 | 25057000 | 127724000 |
| Tuesday, January 1, 2019 | 48473000 | 161524000 |
| Wednesday, January 1, 2020 | 76669000 | 182933000 |
| Friday, January 1, 2021 | 160180000 | 219982000 |
| Saturday, January 1, 2022 | 221227000 | 278139000 |
| Sunday, January 1, 2023 | 264410000 | 309799000 |
| Monday, January 1, 2024 | 284545000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ascendis Pharma A/S and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, Ultragenyx consistently outpaced Ascendis in SG&A spending, reflecting its aggressive market strategies. By 2023, Ultragenyx's SG&A expenses surged by nearly 186% from 2014, reaching approximately $310 million. In contrast, Ascendis saw a staggering increase of over 410%, culminating in around $264 million. This rapid growth in expenses highlights the companies' commitment to expanding their market presence and operational capabilities. Such financial insights are pivotal for investors and stakeholders aiming to gauge the strategic directions of these biotech giants. As the industry evolves, monitoring these trends will be essential for predicting future market dynamics.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.